Alpine Immune Sc Stock Price, News & Analysis

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) has initiated patient enrollment in the RUBY-3 study for autoimmune glomerulonephritis and plans to start the RUBY-4 study for autoimmune cytopenias in Q2 2023. The company expects initial data from both studies by the end of 2023. Financially, Alpine reported a net loss of $57.8 million for 2022, with cash reserves of $273.4 million sufficient to fund operations through 2025. Research expenses rose to $18.8 million, reflecting increased headcount for clinical programs. Collaboration revenue decreased to $2.8 million in Q4 2022, down from $4.5 million in Q4 2021.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) will present posters on March 22 and March 31, 2023, at the ASCPT Annual Meeting and ISN World Congress of Nephrology, respectively. The presentations will cover the early clinical pharmacokinetics of Povetacicept (ALPN-303), a dual BAFF/APRIL antagonist targeting autoimmune and inflammatory diseases. The RUBY-1 Phase 1 Study has shown that Povetacicept is well tolerated at doses up to 960 mg, with promising pharmacokinetics and effects on immunoglobulins, supporting further clinical developments.

On March 18, 2023, Alpine Immune Sciences (NASDAQ: ALPN) will present clinical data from the RUBY-1 Phase 1 study of povetacicept at the American Academy of Dermatology Annual Meeting. The study focuses on the safety, tolerability, pharmacokinetics, and pharmacodynamics of povetacicept, a dual B cell cytokine antagonist targeting autoimmune blistering diseases. Results indicate that povetacicept is well tolerated at doses up to 960 mg, demonstrating dose-dependent pharmacokinetics and significant reductions in immunoglobulins. This paves the way for future clinical advancements.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced it will release its fourth quarter and full year 2022 financial results on March 23, 2023, after market close. A corresponding conference call and webcast is scheduled for 4:30 p.m. ET the same day. The company focuses on developing innovative immunotherapies for autoimmune and inflammatory diseases, supported by a robust R&D platform and strategic collaborations with leading biopharmaceutical firms. More details can be found on the investor relations section of their website.

Alpine Immune Sciences (NASDAQ: ALPN) will participate in two healthcare conferences this March. On March 7, at 10:30 AM ET, the company will join a corporate panel on autoimmune diseases during the Cowen Healthcare Conference. Following this, on March 14, at 3:20 PM ET, Alpine will engage in a fireside chat at the Oppenheimer Healthcare Conference. Live webcasts of both events will be accessible on the company's investor relations website, with replays available for 90 days afterward. This participation underscores Alpine's commitment to developing innovative treatments for autoimmune and inflammatory diseases.

Alpine Immune Sciences (NASDAQ: ALPN) announced its participation in the SVB Securities Global Biopharma Conference on February 16, 2023, at 12:00 p.m. ET. The company will present a corporate overview and host investor meetings. A live webcast will be accessible through the investor relations section of their website, with a 90-day replay afterward. Alpine focuses on developing innovative immunotherapies for autoimmune and inflammatory diseases, leveraging advanced protein engineering technologies. The company aims to create best-in-class multifunctional therapies and has formed strategic collaborations for its clinical and preclinical pipeline.